iShares Nasdaq Biotechnology ETF (IBB)

NASDAQ: IBB · IEX Real-Time Price · USD
114.42
-2.10 (-1.80%)
May 18, 2022 12:15 PM EDT - Market open
Assets$7.39B
NAV$113.36
Expense Ratio0.45%
PE Ratio16.49
Shares Out65.15M
Dividend (ttm)$0.31
Dividend Yield0.27%
Ex-Dividend DateMar 24, 2022
1-Year Return-23.88%
Volume847,856
Open114.52
Previous Close116.52
Day's Range114.27 - 115.96
52-Week Low105.39
52-Week High177.37
Beta0.90
Holdings377
Inception DateFeb 5, 2001

About IBB

The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Asset ClassEquity
SectorBiotech
RegionGlobal
IssuerBlackRock iShares
Stock ExchangeNASDAQ
Ticker SymbolIBB
Index TrackedNASDAQ Biotechnology Index

Top 10 Holdings

53.42% of assets
NameSymbolWeight
AmgenAMGN9.60%
Gilead SciencesGILD8.32%
Regeneron PharmaceuticalsREGN7.25%
Vertex PharmaceuticalsVRTX6.86%
ModernaMRNA5.05%
IQVIA HoldingsIQV4.00%
IlluminaILMN3.19%
BiogenBIIB3.10%
BioNTech SEBNTX3.09%
Mettler-Toledo InternationalMTD2.95%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Mar 24, 2022$0.11756Mar 30, 2022
Dec 13, 2021$0.04129Dec 17, 2021
Sep 24, 2021$0.12441Sep 30, 2021
Jun 10, 2021$0.02324Jun 16, 2021
Mar 25, 2021$0.13106Mar 31, 2021
Full Dividend History

News

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Other symbols:AMGNBBHBIIBGILDXBI
1 week ago - Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

1 week ago - Zacks Investment Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

2 weeks ago - Zacks Investment Research

Biotech ETFs Could Be in for More Pain Ahead

After suffering one of their worst Aprils in years, biotech sector-related exchange traded funds could be in for even more pain ahead. Year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI) has declined...

Other symbols:XBI
2 weeks ago - ETF Trends

Is Biotech ripe for investment yet?

It's a great time to be looking for opportunities in biotech as the sector is near the bottom, says MPM Capital's Dr Christiana Bardon. Biotech has been in correction over the past eight months What man...

1 month ago - Invezz

Positioning for Biotech Bounceback

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that b...

Other symbols:BBCBBHSBIO
1 month ago - ETF Trends

Cantor's Louise Chen on how more Covid booster shots could affect pharma stocks

Louise Chen, Cantor Fitzgerald analyst, joins 'Squawk on the Street' to discuss whether or not the prospect for more boosters mean anything for revenue trajectory in pharmaceutical stocks, if Chen think...

1 month ago - CNBC Television

Jefferies' Michael Yee explains his top biotech picks: VRTX, FATE, ZLAB

Michael Yee, Jefferies, joins 'The Exchange' to discuss what's driving the biotech bounce and his top picks. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIv...

Other symbols:FATEVRTXXBIZLAB
1 month ago - CNBC Television

Biotech Stocks, ETFs Starting to Look Healthier

Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALPS ...

Other symbols:BBCBBHSBIO
1 month ago - ETF Trends

Investors Should Take a Look at the Beaten Down Biotech ETFs

Biotechnology sector-related exchange traded funds are on a four-day streak and gaining momentum, breaking above their short-term trend lines. On Friday, SPDR S&P Biotech ETF (NYSEArca: XBI) rose 2.9% w...

Other symbols:XBI
1 month ago - ETF Trends

Biotech will face challenges this year, says Jefferies' Michael Yee

Michael Yee, Jefferies equity research analyst, joins 'Closing Bell' to discuss Moderna stocks.

1 month ago - CNBC Television

Pharma will move higher, but Oppenheimer's Holz is hesitant on valuations

Oppenheimer's Jared Holz digs in on health care stocks. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Guy Adami and Jeff Mills.

Other symbols:ABBVLLYXBI
2 months ago - CNBC Television

I think this correction will turn into a bull market, says Reynolds Strategy's Brian Reynolds

Brian Reynolds, chief market strategist at Reynolds Strategy, joins 'The Exchange' to discuss his outlook on the markets.

Other symbols:XBI
2 months ago - CNBC Television

Raymond James: Small-cap biotechs on track for 'worst 12-month run' in decades

Small-cap biotechnology companies are on track for the worst 12 months in more than 15 years when compared with their large-cap biotech peers, according to Raymond James analysts. Small-cap biotechs out...

Other symbols:XBI
2 months ago - Market Watch

SBIO Is a Good Place to Be for Biotech Innovation

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare sect...

Other symbols:BBCBBHSBIO
2 months ago - ETF Trends

How Are Biotech ETFs Reacting to These Q4 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Other symbols:BBHXBI
3 months ago - Zacks Investment Research

Biotech ETFs Muddled Despite Amgen Strength

Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share buy...

Other symbols:BBHIBBQ
3 months ago - ETF Trends

Biotech is an opportunity right now, says Trivariate Research CEO

Adam Parker, founder and CEO of Trivariate Research, joins 'Closing Bell' how to invest in the tech sector.

3 months ago - CNBC Television

Final Trades: Deere, Qualcomm, Biotech & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols:DEQCOMON
3 months ago - CNBC Television

3 Growth ETFs to Consider Buying During This Correction

They've taken a beating, but the industries they track are still growing.

Other symbols:MSOSXBI
3 months ago - The Motley Fool

Play 5 High-Beta ETF Areas for January & Be a Bottom Fisher

J.P. Moggan strategists believe that these high-beta ETF areas could winning picks for January 2022.

Other symbols:BETZHACKIPAYONLN
4 months ago - Zacks Investment Research

Top health care analysts weigh in on what's ahead for the sector in 2022

Les Funtleyder of E Squared Capital Management and Geoff Porges of SVB Leerink discuss the state of the health care sector heading into the new year, including whether biotech can recover from a slump i...

Other symbols:XBIXLV
4 months ago - CNBC Television

Biotech M&A Could Finally Perk Up in 2022

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, mark...

Other symbols:BBCBBHSBIO
4 months ago - ETF Trends

ETF Battles: IBB Vs XBI

Which biotech ETF is the better choice?

Other symbols:XBI
4 months ago - ETFcom

Josh Brown on biotech: I really don't think there will be any activity on drug prices next year

The "Halftime" crew discuss whether investors should position themselves in biotech in 2022.

Other symbols:XBI
4 months ago - CNBC Television